- cafead Apr 03, 2023 at 09:42: AM
via Coya Therapeutics has reported data from an academic clinical study of its investigational proprietary biologic, COYA 301, in Alzheimer’s disease (AD) patients.
The open-label, proof-of-concept clinical trial was designed for assessing the tolerability, safety, blood biomarkers, regulatory T cell (Treg) function, and preliminary efficacy of COYA 301 in eight mild-to-moderate AD patients.
article source
The open-label, proof-of-concept clinical trial was designed for assessing the tolerability, safety, blood biomarkers, regulatory T cell (Treg) function, and preliminary efficacy of COYA 301 in eight mild-to-moderate AD patients.
article source